UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Cancer discovery, 2014-09, Vol.4 (9), p.1046-1061

2014

Volltextzugriff (PDF)

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Molecular cell, 2009-06, Vol.34 (6), p.641-651

2009

Volltextzugriff (PDF)

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (38), p.E3595-E3604

2013

Volltextzugriff (PDF)

HER2 missense mutations have distinct effects on oncogenic signaling and migration

Proceedings of the National Academy of Sciences - PNAS, 2015-11, Vol.112 (45), p.E6205-E6214

2015

Volltextzugriff (PDF)

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Science signaling, 2016-03, Vol.9 (421), p.ra33

2016

Volltextzugriff (PDF)

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Cancer cell, 2021-08, Vol.39 (8), p.1099-1114.e8

2021

Volltextzugriff (PDF)

EpCAM: Another Surface-to-Nucleus Missile

Cancer cell, 2009-03, Vol.15 (3), p.165-166

2009

Volltextzugriff (PDF)

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Cancer cell, 2020-02, Vol.37 (2), p.183-199.e5

2020

Volltextzugriff (PDF)

Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

Nature communications, 2021-03, Vol.12 (1), p.1382-15, Article 1382

2021

Volltextzugriff (PDF)

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

Cancer discovery, 2015-11, Vol.5 (11), p.1155-1163

2015

Volltextzugriff (PDF)

Functional Effects of Glycosylation at Asn-579 of the Epidermal Growth Factor Receptor

Biochemistry (Easton), 2005-11, Vol.44 (45), p.14920-14931

2005

Volltextzugriff (PDF)

Maximizing the benefits of off-target kinase inhibitor activity

Cancer discovery, 2013-02, Vol.3 (2), p.138-140

2013

Volltextzugriff (PDF)

Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2 -mutant breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P4-P4-01-02

2022

Volltextzugriff (PDF)

Abstract 867: EGFR kinase domain duplication (EGFR-KDD) is activated by asymmetric intra-molecular dimerization

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.867-867

2019

Volltextzugriff (PDF)

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

JNCI : Journal of the National Cancer Institute, 2017-11, Vol.109 (11)

2017

Volltextzugriff (PDF)

Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.GS6-04-GS6-04

2020

Volltextzugriff (PDF)

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA.sup.H1047R in HER2/ER-positive breast cancer

Breast cancer research and treatment, 2016-12, Vol.160 (3), p.457

2016

Volltextzugriff (PDF)

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA super(H1047R) in HER2/ER-positive breast cancer

Breast cancer research and treatment, 2016-12, Vol.160 (3), p.457-474

2016

Volltextzugriff (PDF)

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA ^sup H1047R^ in HER2/ER-positive breast cancer

Breast cancer research and treatment, 2016-12, Vol.160 (3), p.457

2016

Volltextzugriff (PDF)

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CAH1047R in HER2/ER-positive breast cancer

Breast cancer research and treatment, 2016-10, Vol.160 (3), p.457-474

2016

Volltextzugriff (PDF)

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

Breast cancer research and treatment, 2016-12, Vol.160 (3), p.457-474

2016

Volltextzugriff (PDF)

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Cancer cell, 2020-02, Vol.37 (2), p.258-259

2020

Volltextzugriff (PDF)

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer

The Journal of clinical investigation, 2014-12, Vol.124 (12), p.5490-5502

2014

Volltextzugriff (PDF)

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (38), p.15178-15178

2013

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)
Dissertationen
(1)

Sprache

Englisch
(33)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Humans
(16)
Life Sciences & Biomedicine
(14)
Mutation
(10)
Oncology
(10)
Animals
(9)
Cell Line, Tumor
(9)
Female
(8)
Cell Biology
(7)
Drug Resistance, Neoplasm - Genetics
(7)
Breast Neoplasms - Drug Therapy
(6)
Mice
(6)
Protein Kinase Inhibitors - Pharmacology
(6)
Breast Cancer
(5)
Breast Neoplasms - Genetics
(5)
Erbb Receptors - Chemistry
(5)
Erbb Receptors - Genetics
(5)
Phosphorylation
(5)
Receptor, Erbb-2 - Genetics
(5)
Antineoplastic Agents - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

HER2 missense mutations have distinct effects on oncogenic signaling and migration

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

EpCAM: Another Surface-to-Nucleus Missile

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

Functional Effects of Glycosylation at Asn-579 of the Epidermal Growth Factor Receptor

Maximizing the benefits of off-target kinase inhibitor activity

Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2 -mutant breast cancer

Abstract 867: EGFR kinase domain duplication (EGFR-KDD) is activated by asymmetric intra-molecular dimerization

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA.sup.H1047R in HER2/ER-positive breast cancer

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA super(H1047R) in HER2/ER-positive breast cancer

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA ^sup H1047R^ in HER2/ER-positive breast cancer

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CAH1047R in HER2/ER-positive breast cancer

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

Suchergebnisse filtern